Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Daniel S Chen"'
Autor:
Chiung-Hung Chang, Bi Yu, Chiu-Hsian Su, Daniel S Chen, Yu-Chi Hou, Yueh-Sheng Chen, Yuan-Man Hsu
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105362 (2014)
Salmonella, a common zoonotic pathogen, causes gastroenteritis in both humans and animals. Traditional Chinese Medicine (TCM) has been used to improve gastrointestinal dysfunction and to modify the immune response to inflammation for centuries. This
Externí odkaz:
https://doaj.org/article/24550bc15c5941fc88014e19263f20f6
Autor:
Elizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, Heidi Savage, Ajay Pandita, Ru-Fang Yeh, Andrea Pirzkall, Bernard M Fine, Lukas C Amler, Daniel S Chen, Mark R Lackner
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12517 (2010)
Evaluation of cancer biomarkers from blood could significantly enable biomarker assessment by providing a relatively non-invasive source of representative tumor material. Circulating Tumor Cells (CTCs) isolated from blood of metastatic cancer patient
Externí odkaz:
https://doaj.org/article/f38c38ef1872463483198588d1a90475
Autor:
Daniel S Chen, Yoav Soen, Tor B Stuge, Peter P Lee, Jeffrey S Weber, Patrick O Brown, Mark M Davis
Publikováno v:
PLoS Medicine, Vol 2, Iss 10, p e265 (2005)
BackgroundIn contrast to many animal model studies, immunotherapeutic trials in humans suffering from cancer invariably result in a broad range of outcomes, from long-lasting remissions to no discernable effect.Methods and findingsIn order to study t
Externí odkaz:
https://doaj.org/article/2d393b24e4b74f30aee22a64584a7cd9
Autor:
Daniel S. Chen, Priti S. Hegde
Publikováno v:
Immunity. 52:17-35
Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there i
Autor:
Laura A. Levit, Steven D. Averbuch, Kathryn F. Mileham, Apostolia Maria Tsimberidou, Richard L. Schilsky, John M. Kirkwood, Daniel S. Chen, Elad Sharon, Lisa M. McShane, Michael A. Postow
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Purpose To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. Methods ASCO and the Society for Immunotherapy of Cancer (SITC) con
Autor:
Charles G. Drake, Walter J. Urba, David Kaufman, Leisha A. Emens, Jeffrey S. Weber, Alessandra Cesano, Douglas G. McNeel, Ana C. Anderson, Marcela V. Maus, Mario Sznol, Jon M Wiggington, Lisa H. Butterfield, Patrick Hwu, David Parkinson, Ernest C. Borden, James L. Gulley, Michael J. Mastrangelo, Michael B. Atkins, Kim Margolin, Julie R. Brahmer, Thomas F. Gajewski, Robert O. Dillman, Pedro Romero, Daniel S. Chen, Francesco M. Marincola, George J. Weiner, Paolo A. Ascierto, Tanja D. de Gruijl, Michael T. Lotze, Paul M. Sondel, F. Stephen Hodi, Bernard A. Fox, Stefani Spranger, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for immunotherapy of cancer, vol. 8, no. 1
Ascierto, P A, Fox, B, Urba, W, Anderson, A C, Atkins, M B, Borden, E C, Brahmer, J, Butterfield, L H, Cesano, A, Chen, D, De Gruijl, T, Dillman, R O, Drake, C G, Emens, L A, Gajewski, T F, Gulley, J L, Stephen Hodi, F, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, D G, Margolin, K, Marincola, F, Mastrangelo, M J, Maus, M V, Parkinson, D R, Romero, P J, Sondel, P M, Spranger, S, Sznol, M, Weiner, G J, Wiggington, J M & Weber, J S 2020, ' Insights from immuno-oncology : The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 ', Journal for Immunotherapy of Cancer, vol. 8, no. 1, e000878 . https://doi.org/10.1136/jitc-2020-000878
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
Journal for immunotherapy of cancer, vol. 8, no. 1
Ascierto, P A, Fox, B, Urba, W, Anderson, A C, Atkins, M B, Borden, E C, Brahmer, J, Butterfield, L H, Cesano, A, Chen, D, De Gruijl, T, Dillman, R O, Drake, C G, Emens, L A, Gajewski, T F, Gulley, J L, Stephen Hodi, F, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, D G, Margolin, K, Marincola, F, Mastrangelo, M J, Maus, M V, Parkinson, D R, Romero, P J, Sondel, P M, Spranger, S, Sznol, M, Weiner, G J, Wiggington, J M & Weber, J S 2020, ' Insights from immuno-oncology : The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 ', Journal for Immunotherapy of Cancer, vol. 8, no. 1, e000878 . https://doi.org/10.1136/jitc-2020-000878
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 (SARS-COV-2) virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in
Autor:
Mario Perro, Vaios Karanikas, Marcin Kowanetz, Andreas Roller, Christian Klein, Marieke F. Fransen, Ines Matos, Stefano Sammicheli, Stanford Chen, Eva Sum, Pablo Umana, Vesna Pulko, Christian Jost, Regula B. Buser, Daniel S. Chen, Priti S. Hegde, Ferry Ossendorp, Sara Colombetti, Maud Léa Mayoux, Wei Xu, Anton Belousov, Karolin Rommel
Publikováno v:
Mayoux, M, Roller, A, Pulko, V, Sammicheli, S, Chen, S, Sum, E, Jost, C, Fransen, M F, Buser, R B, Kowanetz, M, Rommel, K, Matos, I, Colombetti, S, Belousov, A, Karanikas, V, Ossendorp, F, Hegde, P S, Chen, D S, Umana, P, Perro, M, Klein, C & Xu, W 2020, ' Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy ', Science Translational Medicine, vol. 12, no. 534, eaav7431 . https://doi.org/10.1126/scitranslmed.aav7431
Science Translational Medicine, 12(534):eaav7431. American Association for the Advancement of Science
Science Translational Medicine, 12(534). AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 12(534):eaav7431. American Association for the Advancement of Science
Science Translational Medicine, 12(534). AMER ASSOC ADVANCEMENT SCIENCE
PD-L1/PD-1 blocking antibodies have demonstrated therapeutic efficacy across a range of human cancers. Extending this benefit to a greater number of patients, however, will require a better understanding of how these therapies instigate anticancer im
Autor:
Axel Hoos, Mizuki Nishino, Marcus Ballinger, Benjamin Lyons, F. Stephen Hodi, Chris McKenna, Gregg Fine, Thomas Powles, Daniel S. Chen, Ulrich Beyer, Josep Tabernero, Jean Charles Soria, Ina Rhee, Nathan Winslow, Jedd D. Wolchok, David Smith
Publikováno v:
Journal of Clinical Oncology. 36:850-858
Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately captured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. We describe immune
Autor:
Herbert Hurwitz, Daniel S. Chen
Publikováno v:
The Cancer Journal. 24:193-204
Cancer immunotherapy (CIT) has transformed cancer treatment. In particular, immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 pathway have demonstrated durable clinical benefit in some patients. However, CIT combinati
Autor:
Elizabeth Budde, Catherine Diefenbach, Iris Sison, Ian W. Flinn, Philippe Armand, Genevive Hernandez, Ajay K. Gopal, Ibrahim Qazi, Loretta J. Nastoupil, Maya Leabman, Matthew J. Matasar, Won Seog Kim, Gareth P. Gregory, Bruce Keyt, Daniel S. Chen, Chan Yoon Y. Cheah, Ching-Fai Pang
Publikováno v:
Blood. 138:132-132
Introduction : IGM-2323 is the first engineered high-affinity, high-avidity bispecific IgM monoclonal antibody TCE to be tested in the clinic. It has 10 binding domains for CD20 and a single binding domain for CD3 and is designed to bind irreversibly